AKAP8L

Across TCGA pan-cancer cohorts, AKAP8L mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated AKAP8L data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher AKAP8L mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated AKAP8L expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

HNSC, COAD, and LUAD are the cancer types where AKAP8L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.771	0.926	<.001	116	view →
COAD	DFS	Tertile	All	1.000	0.920	.045	12	view →
LUAD	OS	Tertile	III,IV	0.845	0.278	.005	11	view →
PDAC	OS	Median	IV	0.951	0.381	.006	8	view →
CCRCC	OS	Median	All	0.914	1.000	.027	8	view →
OV	DFS	Median	All	0.868	1.000	.037	4	view →
UCEC	OS	Quartile	All	0.899	1.000	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

AKAP8L–HNSC (OS)

Open the HNSC breakdown →